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OBJECTIVES We sought to investigate whether early and late outcome after percutaneous transluminal
coronary angioplasty (PTCA) could be predicted by baseline levels of acute-phase reactants.
BACKGROUND Although some risk factors for acute complications and restenosis have been identified, an
accurate preprocedural risk stratification of patients undergoing PTCA is still lacking.
METHODS Levels of C-reactive protein (CRP), serum amyloid A protein (SAA) and fibrinogen were
measured in 52 stable angina and 69 unstable angina patients undergoing single vessel PTCA.
RESULTS Tertiles of CRP levels (relative risk [RR] 5 12.2, p , 0.001), systemic hypertension (RR 5
4.3, p 5 0.046) and female gender (RR 5 4.1, p 5 0.033) were the only independent
predictors of early adverse events. Intraprocedural and in-hospital complications were
observed in 22% of 69 patients with high serum levels (.0.3 mg/dl) of CRP and in none of
52 patients with normal CRP levels (p , 0.001). Tertiles of CRP levels (RR 5 6.2, p 5
0.001), SAA levels (RR 5 6.0, p 5 0.011), residual stenosis (RR 5 3.2, p 5 0.007) and acute
gain (RR 5 0.3, p 5 0.01) were the only independent predictors of clinical restenosis. At
one-year follow-up, clinical restenosis developed in 63% of patients with high CRP levels and
in 27% of those with normal CRP levels (p , 0.001).
CONCLUSIONS Preprocedural CRP level, an easily measurable marker of acute phase response, is a powerful
predictor of both early and late outcome in patients undergoing single vessel PTCA,
suggesting that early complications and clinical restenosis are markedly influenced by the
preprocedural degree of inflammatory cell activation. (J Am Coll Cardiol 1999;34:1512–21)
© 1999 by the American College of Cardiology
Percutaneous transluminal coronary angioplasty (PTCA) is
an established myocardial revascularization procedure; how-
ever, restenosis rate ranges from 30% to 60% (1), and in
unstable patients the risk of acute complications ranges from
5% to 30% (2,3).
Preprocedural identification of low-risk and high-risk
patients who might benefit from additional procedures (4,5)
would be desirable. However, the predictors of acute com-
plications (3,6–12) and restenosis (13–18) considered so far
have a low predictive value (7,9,18), are available only after
the procedure (11,17) or are not easily applicable in clinical
practice (10–12,15,16).
In vitro enhanced cytokine synthesis by peripheral blood
monocytes before PTCA has been found to predict late
lumen loss, suggesting that preprocedural activation of
inflammatory cells may play a role in the modulation of
vessel wall response to the injury induced by balloon PTCA
(16). This possibility is supported by experimental and
clinical studies showing that acute phase reactants and
proinflammatory cytokines promote leukocyte, endothelial
and smooth muscle cell activation, resulting in an increase in
procoagulant activity (19), metalloproteinase release (20)
and neointimal proliferation (21).
C-reactive protein (CRP), serum amyloid A protein
(SAA) and fibrinogen are easily measurable acute-phase
reactants, which are synthesized in response to proinflam-
matory cytokines (22). They have been consistently associ-
ated with prognosis in ischemic heart disease (23–26).
Therefore, we investigated the short- and long-term prog-
nostic value of preprocedural serum levels of CRP, SAA and
fibrinogen in patients with stable and unstable angina
undergoing single-vessel PTCA.
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METHODS
Patients. The study population consisted of 121 of 219
consecutive patients who underwent PTCA on a single
nonocclusive coronary stenosis; 52 had stable angina and 69
had unstable angina (Table 1).
Exclusion criteria were: myocardial infarction (MI)
within three months (28 patients), multilesion PTCA (15
patients), total occlusion (8 patients), previous PTCA or
bypass surgery (27 patients), left ventricular ejection fraction
,30% (12 patients), left bundle branch block (3 patients)
and intercurrent inflammatory conditions known to be
associated with an acute phase response (5 patients). At the
time of PTCA, all patients were on oral aspirin.
The protocol was approved by the Ethics Committee of
the Catholic University of Rome; all patients gave informed
consent.
Blood sampling. Peripheral blood samples for measure-
ment of CRP, SAA and fibrinogen were taken immediately
before PTCA. Coded plasma samples were stored at 270°C
and analyzed in a single batch at the end of the study; thus,
patient management was independent of these results.
Laboratory assays. C-reactive protein and SAA were as-
sayed by an automated monoclonal antibody solid phase
sandwich-type enzyme immunoassay on the Abbott IMX
instrument (Abbott Laboratories, North Chicago, Illinois)
(27,28). Fibrinogen was measured by the thrombin time
method, as described by Clauss (29).
For data analysis, the overall population was grouped in
tertiles according to preprocedural levels of CRP, SAA and
fibrinogen. Moreover, elevated preprocedural levels were
defined as: those above 0.3 mg/dl for CRP levels (i.e., 90th
percentile of the normal distribution) (23), above 0.5 mg/dl
for SAA levels (i.e., 82th percentile of the normal distribu-
tion) (23) and above 350 mg/dl for fibrinogen (26).
Coronary angioplasty. The procedure was performed us-
ing a steerable balloon catheter system via the femoral route.
All patients received heparin at the dose required to main-
tain the activated clotting time above 300 s throughout the
procedure.
Coronary angiography: qualitative and quantitative as-
sessment. Coronary angiograms were independently re-
viewed by two expert angiographers who were unaware of
the patients’ clinical and analytic data. Angiographic lesion
morphology before PTCA was categorized according to
Ambrose et al. (30) and to a modified scheme of American
College of Cardiology/American Heart Association Task
Force classification (9). Minimal luminal diameter, refer-
ence diameter, percent diameter stenosis, acute gain and
balloon/vessel ratio were assessed by computerized quanti-
tative angiography (Medis, Nuenen, Netherlands). Proce-
dural angiograms were also analyzed for Thrombolysis in
Myocardial Infarction (TIMI) flow grade (31), the appear-
ance of intracoronary thrombi (intraluminal filling defects or
contrast medium staining within the lumen) and luminal
dissection (9). Percutaneous transluminal coronary angio-
plasty was considered successful if the final percent diameter
stenosis was less than 50% with TIMI 3 flow in the absence
of death, recurrent ischemia, MI (creatine kinase increase to
more than two times the upper limit of normal with or
without evidence of new Q-waves), need of bailout stenting
or urgent coronary bypass graft surgery (CABG) during
the hospital period. Angiographic restenosis was defined as
Abbreviations and Acronyms
CABG 5 coronary bypass graft surgery
CI 5 confidence interval
CRP 5 C-reactive protein
ECG 5 electrocardiogram
MI 5 myocardial infarction
PTCA 5 percutaneous transluminal coronary angioplasty
RR 5 relative risk
SAA 5 serum amyloid A protein
TIMI 5 Thrombolysis in Myocardial Infarction
Table 1. Clinical, Angiographic and Procedural Characteristics
Patients
n 5 121
Age, yr 60 6 10
Male, n (%) 90 (74)
Systemic hypertension, n (%) 63 (52)
Diabetes mellitus, n (%) 29 (24)
Hypercholesterolemia, n (%) 48 (40)
Cigarette smoking, n (%) 80 (66)
Canadian class I–II/III–IV, n (%) 29 (24)/23 (19)
Braunwald class IIB/IIIB, n (%) 38 (31)/31 (26)
Refractory unstable angina, n (%) 10 (8)
Dilated coronary artery:
Left anterior descending, n (%) 76 (63)
Left circumflex, n (%) 23 (19)
Right coronary artery, n (%) 22 (18)
Target stenosis before PTCA:
Percent diameter, % 79 6 11
Minimal lumen diameter, mm 0.6 6 0.3
Type E2,* n (%) 18 (15)
Type B2-C,† n (%) 32 (26)
Small vessel (,3.0 mm), n (%) 73 (60)
Multivessel disease,‡ n (%) 34 (28)
Inflation pressure, atm 6.7 6 2.3
Total inflation time, s 448 6 269
Balloon/vessel ratio 1.0 6 0.1
Acute gain, mm 1.5 6 0.6
Target stenosis after PTCA:
Percent diameter, % 31 6 11
Minimal lumen diameter, mm 2.1 6 0.4
*Ambrose et al. (30) classification. †Modified scheme from American College of
Cardiology/American Heart Association Task Force classification (9). ‡Presence of
.75% diameter stenosis in two or three major epicardial vessels.
PTCA 5 percutaneous transluminal coronary angioplasty; s 5 second.
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more than 50% stenosis in a previously successfully dilated
lesion.
Follow up. After the procedure, all patients had creatine
kinase measurements every 6 h for 24 h and daily recording
of symptoms and electrocardiogram (ECG) until hospital
discharge (4 6 2 days after the procedure). All patients were
discharged on diltiazem and aspirin; other drugs were used
if clinically indicated. Clinical examinations and treadmill
stress tests were performed at 1, 3, 6 and 12 months.
Coronary angiography was repeated in patients with evi-
dence of clinical restenosis as defined below.
End points. The following intraprocedural and predis-
charge complications were considered as early adverse events:
1) abrupt occlusion, defined as an acute flow reduction
(TIMI 0–1);
2) threatened abrupt occlusion, defined as luminal dissec-
tion (type D-E) (9) or new thrombus appearance with
delayed runoff of contrast or TIMI grade 2 flow; or
3) early recurrence of ischemia, defined as rest angina
associated with transient ECG signs of myocardial
ischemia or MI before hospital discharge.
At follow-up, the primary end point was the clinical
evidence of restenosis within one year after hospital dis-
charge. Clinical restenosis was defined as the recurrence or
worsening of ischemic symptoms (typical angina, MI or
death) or ischemia at exercise testing ($1 mm ST segment
depression). Only patients with clinical evidence of resten-
osis underwent repeat coronary angiography.
The need for repeat coronary revascularization, PTCA or
CABG, was also evaluated.
Statistical analysis. Continuous variables with normal dis-
tribution are expressed as mean 6 SD and compared by t
tests; CRP, SAA and fibrinogen values, not normally
distributed, are presented as median and range and com-
pared by Mann-Whitney U test. Correlations were deter-
mined using Spearman’s rank correlation test. Categorical
variables were compared by Fisher exact test or chi-square
statistics, as indicated; when rates of events were calculated
for each tertile of distribution of a continuous variable
(CRP, SAA and fibrinogen levels), the test for linear
association (Mantel-Haenszel) was also applied. Logistic
regression analysis was performed to determine predictors of
early and late adverse events (univariate and forward step-
wise analysis). The chi-square model was used to test the
significance of the coefficients for all the terms in the model.
To verify whether the model fit the data reasonably well, the
Hosmer-Lemeshow Goodness-of-Fit statistics were com-
puted. Event free survival at follow-up was analyzed by Cox
proportional hazards regression model. Tertile distribution
of CRP, SAA and fibrinogen levels, as well as several
clinical and angiographic variables listed in Table 1, were
included in the regression analysis. In addition, CRP, SAA
and fibrinogen levels were included in the regression anal-
ysis as continuous variables after their logarithmic transfor-
mation in order to obtain a nearly normal distribution.
The statistical analysis was performed using the Statistical
Package for Social Sciences software (SPSS 8.0 for Win-
Table 2. Baseline Levels of C-Reactive Protein, Serum Amyloid A Protein and Fibrinogen
Stable Angina
n 5 52
Unstable Angina
n 5 69
p
Value
C-reactive protein
Median values (range), mg/dl 0.26 (0.01–18.7) 0.74 (0.01–11.9) , 0.001
Number of patients with .0.3 mg/dl (%) 15 (29) 5 (78) , 0.001
Tertile distribution: , 0.001
I tertile (,0.28 mg/dl), n (%) 27 (52) 12 (17)
II tertile (,0.82 mg/dl), n (%) 18 (35) 24 (35)
III tertile (.0.82 mg/dl), n (%) 7 (13) 33 (48)
Serum amyloid A protein
Median values (range), mg/dl 0.30 (0.09–20.5) 0.87 (0.09–15.9) , 0.001
Number of patients with .0.5 mg/dl (%) 11 (21) 47 (68) , 0.001
Tertile distribution: , 0.001
I tertile (,0.30 mg/dl), n (%) 25 (48) 13 (19)
II tertile (,0.88 mg/dl), n (%) 21 (40) 22 (32)
III tertile (.0.88 mg/dl), n (%) 6 (12) 34 (49)
Fibrinogen
Median values (range), mg/dl 260 (162–794) 336 (196–880) , 0.001
Number of patients with .350 mg/dl (%) 7 (14) 34 (49) , 0.001
Tertile distribution: , 0.001
I tertile (,264 mg/dl), n (%) 27 (52) 13 (19)
II tertile (,351 mg/dl), n (%) 18 (35) 23 (33)
III tertile (.351 mg/dl), n (%) 7 (13) 33 (48)
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dows, SPSS Inc., Chicago, Illinois). A p value , 0.05 was
considered statistically significant.
RESULTS
Baseline characteristics. Clinical characteristics, angio-
graphic findings and procedural variables are summarized
in Table 1. Before PTCA, elevated levels of CRP
(.0.3 mg/dl), SAA (.0.5 mg/dl) and fibrinogen
(.350 mg/dl) were observed in 29%, 21% and 14%,
respectively, of patients with stable angina and in 78%, 68%
and 49%, respectively, of patients with unstable angina (all
p , 0.001 vs. stable angina) (Table 2). Serum amyloid A
protein levels were closely correlated with CRP levels (r 5
0.91, p , 0.0001), and fibrinogen levels were weakly
correlated with CRP (r 5 0.43, p , 0.001) and SAA levels
(r 5 0.48, p , 0.001).
Early adverse events. Fifteen early adverse events were
observed in the whole population (12%), 2 in stable and 13
in unstable patients (p 5 0.01). Twelve acute or threatened
acute occlusions occurred during the procedure. The re-
maining three adverse events occurred before hospital dis-
charge: two patients developed an acute MI and one patient
had recurrence of rest angina. Percutaneous transluminal
coronary angioplasty failed in 10 patients: urgent CABG in
5 patients, bailout stenting in 2 patients, in-hospital recur-
rence of ischemia in 3 patients. Early adverse events,
treatments and outcome are reported in detail in Table 3.
Stable angina. Among the 52 patients, two (4%) had an
early adverse event: one had an acute occlusion, the other
had a threatened acute occlusion. They had elevated levels
of CRP (2.2 and 18.7 mg/dl) and SAA (1.7 and 20.5 mg/dl)
and both were in the top tertile of CRP and SAA levels
(Fig. 1).
Unstable angina. Among the 69 patients, 13 (19%)
had an early adverse event. An acute occlusion occurred in 7,
threatened acute occlusions during the procedure in 3 and
early recurrence of ischemia before hospital discharge in 3.
All unstable angina patients with early adverse events
had elevated levels of CRP (median 2.1, range 0.47 to
11.9 mg/dl) and SAA (median 1.17, range 0.51 to
15.9 mg/dl). The incidence of early adverse events increased
from 0% in the bottom tertile to 30% in the top tertile of
CRP levels (p 5 0.014); a similar trend was observed for
SAA levels (from 0% to 27%, p 5 0.045) (Fig. 1).
Fibrinogen levels did not discriminate against patients with
or without early adverse events (Fig. 1).
Late adverse events. One year follow up was completed in
all 52 patients with stable angina and in 59 patients with
unstable angina (10 patients with failed PTCA were ex-
cluded from follow up).
Clinical restenosis occurred in 51 patients (46%), as
reported in detail in Table 4. Repeat angiography confirmed
a severe (.75%) target lesion restenosis in all but one
patient who did not exhibit any critical stenosis. Ta
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Clinical restenosis rate was similar in patients with stable
or unstable angina (21/52, 40% vs. 30/59, 51%, p 5 0.27).
Clinical restenosis was significantly higher among patients
with elevated levels of CRP (37/59, 63% vs. 14/52, 27%,
p , 0.001), SAA (34/57, 60% vs. 17/54, 32%, p 5 0.003)
and fibrinogen (23/36, 64% vs. 28/75, 37%, p 5 0.009).
Stable angina. Restenosis rates were 30% and 33% in
stable patients with normal levels of CRP and fibrinogen
and 67% and 86%, respectively, in those with elevated levels
(p 5 0.014 and p 5 0.013). Incidence of restenosis
increased from 33% in the I tertile to 86% in the III tertile
for both CRP levels and fibrinogen (p 5 0.046) (Fig. 2). A
similar trend was observed for SAA levels (p 5 0.13)
(Fig. 2).
Figure 1. Incidence of early adverse events by tertiles of CRP,
SAA and fibrinogen in patients with stable (open bars) and
unstable angina (solid bars). All stable angina patients with early
adverse events were in the III tertile of CRP (Mantel-Haenszel
test for linear association: p 5 0.005) and of SAA (Mantel-
Haenszel test for linear association: p 5 0.004). Among unstable
angina patients, the incidence of early adverse events increased
from 0% in the I tertile to 30% in the III tertile of CRP levels
(Mantel-Haenszel test for linear association: p 5 0.013, respec-
tively) and from 0% in the I tertile to 27% in the III tertile of SAA
(Mantel-Haenszel test for linear association: p 5 0.044). Fibrin-
ogen levels did not discriminate between stable and unstable
patients with or without early adverse events (Mantel-Haenszel
test for linear association: p 5 0.44 in stable angina and p 5 0.48
in unstable angina). The incidence of early adverse events was
similar in stable and unstable angina patients in the III tertile of
CRP or SAA. CRP 5 C-reactive protein; SAA 5 serum amyloid
A protein.
Figure 2. Incidence of clinical restenosis by tertiles of CRP, SAA
and fibrinogen in patients with stable (open bars) and unstable
angina (solid bars). In stable angina patients, the incidence of
restenosis increased from 33% in the I tertile to 86% in the III
tertile of CRP and fibrinogen (Mantel-Haenszel test for linear
association: p 5 0.046) and from 32% in the I tertile to 67% in the
III tertile of SAA (p 5 0.13). Among the unstable angina patients
the incidence of restenosis increased from 25% in the I tertile to
72% in the III tertile of CRP (Mantel-Haenszel test for linear
association: p 5 0.004) and from 23% in the I tertile to 67% in the
III tertile of SAA (Mantel-Haenszel test for linear association: p 5
0.010). In patients with unstable angina, fibrinogen levels were not
associated with the incidence of restenosis (p 5 0.65). The
incidence of restenosis was similar in stable and unstable angina
patients in the III tertile of CRP or SAA. CRP 5 C-reactive
protein; SAA 5 serum amyloid A protein.
Table 4. Clinical Events at One Year Follow-Up
All Patients
n 5 111
CRP < 0.3 mg/dl
n 5 52
CRP >0.3 mg/dl
n 5 59 p Value
Asymptomatic 1 normal ET, n (%) 60 (54.1) 38 (73.1) 22 (37.3) , 0.001
Clinical restenosis, n (%) 51 (45.9) 14 (26.9) 37 (62.7) , 0.001
Asymptomatic 1 positive ET, n (%) 4 (3.6) — 4 (6.8) N.S.
CCS I–II angina, n (%) 8 (7.5) 4 (7.7) 4 (7.4) N.S.
CCS III–IV angina, n (%) 11 (10.4) 9 (17.3) 2 (3.7) 0.003
Rest angina, n (%) 23 (21.7) 1 (1.9) 22 (40.7) , 0.001
MI, n (%) 5 (4.5) — 5 (8.5) 0.04
Death, n (%) — — — —
TLR, n (%) 35 (31.6) 10 (19.2) 25 (42.4) 0.009
MI or TLR, n (%) 37 (33.3) 10 (19.2) 27 (45.8) 0.003
CCS 5 Canadian Cardiovascular Society; CRP 5 C-reactive protein; ET 5 exercise test; MI 5 myocardial infarction; TLR 5 target lesion revascularization.
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Unstable angina. Restenosis rates were 20% and 32% in
unstable patients with normal levels of CRP and SAA and
61% and 62%, respectively, in those with elevated levels
(p 5 0.006 and p 5 0.024). An increasing incidence of
restenosis was observed from 25% in the I tertile to 72% in
the III tertile of CRP (p 5 0.004); a similar trend was
observed for SAA (from 23% to 67%, p 5 0.010) (Fig. 2).
Fibrinogen levels were not associated with the incidence of
restenosis (Fig. 2).
Predictors of early and late adverse events. Acute compli-
cations. Tertiles of CRP and SAA levels, unstable angina,
hypertension and female gender were associated with a
higher risk of early adverse events at the univariate regres-
sion analysis. However, CRP tertiles (RR 5 12.2, confi-
dence interval [CI] 5 3.0 to 50.2, III tertile vs. the
remaining two p , 0.001), female gender (RR 4.1, CI 5 1.1
to 14.7, p 5 0.033) and hypertension (RR 5 4.3, CI 5 1.0
to 18.5, p 5 0.046) were the only independent predictors of
early adverse events (chi-square model 5 26.7, df [degrees
of freedom] 5 3, p , 0.001) (Table 5). The risk predicted
by our logistic regression model was well correlated with
observed early adverse events (87% of correct classification;
Hosmer-Lemeshow Goodness-of-Fit, p 5 0.939).
When acute-phase proteins were included in the regres-
sion analysis as continuous variables, CRP levels (RR for log
[CRP] 5 21.9, CI 5 4.7 to 102.1, p , 0.001) were the only
independent predictors of early adverse events (chi-square
model 5 27.4, df 5 1, p , 0.001); after exclusion of other
inflammatory markers, SAA (RR for log [SAA] 5 8.1,
CI 5 2.5 to 26.6, p , 0.001), but not fibrinogen levels,
independently predicted early adverse events. C-reactive
protein levels (RR 5 10.4, CI 5 1.4 to 79.6, III tertile vs.
I tertile, p 5 0.02) were also an independent predictor of the
in-hospital occurrence of death, MI, need of urgent CABG
or repeat revascularization.
Restenosis. Tertiles of CRP, SAA and fibrinogen levels
before PTCA, multivessel disease and residual diameter
stenosis were associated with increased risk of clinical
restenosis at the univariate analysis. However, CRP (RR 5
6.2, CI 5 2.0 to 18.7, III tertile vs. I tertile, p 5 0.001) and
Table 5. Logistic Regression Analysis for Early Adverse Events
Univariate
Relative Risk
(95% CI) p Value
Multivariate
Relative Risk
(95% CI) p Value
Age 1.02 (0.96–1.08) 0.5
Female gender 4.1 (1.3–12.9) 0.013 4.1 (1.1–14.7) 0.033
Diabetes mellitus 1.7 (0.5–5.6) 0.4
Systemic hypertension 4.3 (1.1–16.6) 0.030 4.3 (1.0–18.5) 0.046
Hypercholesterolemia 1.4 (0.5–4.2) 0.6
Smoking 1.03 (0.3–3.3) 0.9
Unstable angina 5.8 (1.2–27.8) 0.025
Braunwald class IIIB 1.5 (0.5–5.0) 0.5
Refractory unstable angina 0.8 (0.1–6.8) 0.8
CRP tertiles:
III vs. I 1 II* 11.7 (3.0–45.9) , 0.001 12.2 (3.0–50.2) , 0.001
III vs. II 5.6 (1.4–2.2) 0.013 5.0 (1.2–20.0) 0.024
SAA tertiles:
III vs. I 1 II* 7.3 (2.1–25.4) 0.001
III vs. II 3.7 (1.04–13.1) 0.039
Fibrinogen tertiles:
III vs. I 1.3 (0.3–5.2) 0.8
II vs. I 1.6 (0.4–6.3) 0.5
III vs. II 1.3 (0.4–4.7) 0.7
Target stenosis
Minimal lumen diameter 1.2 (0.2–6.9) 0.8
Percent diameter stenosis 1.0 (0.9–1.1) 0.9
Left anterior descending 1.1 (0.4–3.4) 0.9
Type E2† 0.8 (0.2–4.0) 0.8
Type B2-C‡ 2.3 (0.7–7.2) 0.1
Small vessel (,3.0 mm) 0.7 (0.2–2.2) 0.6
Multivessel disease§ 1.3 (0.4–4.3) 0.6
Balloon/vessel ratio 1.8 (0.2–13.4) 0.9
*Risk cannot be assessed versus I tertile because of the absence of early adverse events in the I tertile of CRP and SAA levels. †Ambrose et al. classification
(30). ‡Modified scheme from American College of Cardiology/American Heart Association Task Force classification (9). §Presence of .75% diameter
stenosis in two or three major epicardial vessels.
CRP 5 C-reactive protein.
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residual stenosis (RR 5 3.2, CI 5 1.3 to 7.5, .30% vs.
#30% stenosis, p 5 0.007) were the only independent
predictors of restenosis (chi-square model 5 23.6, df 5 3,
p , 0.001) (Table 6). The risk predicted by our multivariate
logistic analysis was closely correlated with observed events
(percentage of correct classification 5 70%; Hosmer-
Lemeshow Goodness-of-Fit, p 5 0.968). Of note is that
elevated CRP levels, compared with low levels, increased
the restenosis rate from 18% to 44% in patients with #30%
residual stenosis and from 37% to 77% in patients with
.30% residual stenosis (Fig. 3). When acute-phase proteins
and residual stenosis were analyzed as continuous variables,
SAA levels (RR for log [SAA] 5 6.0, CI 5 2.3 to 16.2, p ,
0.001), acute gain (RR 5 0.3, CI 5 0.1 to 0.8, p 5 0.011)
and multivessel disease (RR 5 2.7, CI 5 1.0 to 7.0, p 5
0.042) were the only independent predictors of clinical
restenosis (chi-square model 5 25.6, df 5 3, p , 0.001);
after exclusion of other inflammatory markers, CRP [RR for
log [CRP] 5 2.9, CI 5 1.4 to 6.3, p 5 0.004], but not
fibrinogen levels, were also independent predictors of resteno-
sis. Preprocedural CRP levels (RR 5 4.9, CI 5 1.6 to 14.4, III
tertile vs. I tertile, p 5 0.008) were also the most powerful
predictor of major adverse cardiac events (e.g., death, MI or
need for repeat revascularization) at follow-up.
Cox proportional-hazard model was used in order to
evaluate timing of adverse events at follow-up; CRP and
Table 6. Logistic Regression Analysis for Clinical Restenosis at One Year Follow-Up
Univariate
Relative Risk
(95% CI) p Value
Multivariate
Relative Risk
(95% CI) p Value
Age 1.0 (0.9–1.1) 0.5
Female gender 1.4 (0.5–3.5) 0.5
Diabetes mellitus 1.5 (0.6–3.7) 0.4
Systemic hypertension 1.6 (0.8–3.5) 0.2
Hypercholesterolemia 0.7 (0.3–1.4) 0.3
Smoking 1.0 (0.4–2.2) 0.9
Unstable angina 1.5 (0.6–3.3) 0.3
Braunwald class IIIB 1.4 (0.6–3.3) 0.5
Refractory unstable angina 2.5 (0.6–11.0) 0.2
CRP tertiles: , 0.001 0.003
II vs. I 1.4 (0.5–3.5) 0.5 1.4 (0.5–3.7) 0.5
III vs. I 6.7 (2.3–19.7) , 0.001 6.2 (2.0–18.7) 0.001
III vs. II 5.0 (1.8–14.2) 0.002 4.5 (1.5–13.4) 0.005
SAA tertiles: 0.008
II vs. I 2.0 (0.8–5.2) 0.1
III vs. I 4.9 (1.8–13.7) 0.002
III vs. II 2.4 (0.8–5.2) 0.07
Fibrinogen tertiles: 0.029
II vs. I 0.7 (0.3–1.9) 0.5
III vs. I 2.5 (1.0–6.6) 0.049
III vs. II 3.5 (1.3–9.5) 0.011
Target stenosis before PTCA
Minimal lumen diameter 1.6 (0.5–5.5) 0.4
Percent diameter stenosis 0.6 (0.7–1.4) 0.5
Left anterior descending 1.2 (0.5–2.5) 0.7
Type E2* 0.8 (0.3–2.3) 0.7
Type B2-C† 0.7 (0.3–1.8) 0.5
Small vessel (,3.0 mm) 1.2 (0.6–2.3) 0.6
Multivessel disease‡ 2.6 (1.0–6.1) 0.028
Balloon/vessel ratio 1.4 (0.2–10.4) 0.9
Total inflation time 1.0 (0.9–1.0) 0.9
Inflation pressure 1.0 (0.9–1.1) 0.9
Target stenosis after PTCA
Minimal lumen diameter 0.4 (0.1–1.1) 0.6
Percent diameter stenosis 1.05 (1.0–1.1) 0.007
.30% residual stenosis 1.9 (1.3–2.8) 0.002 3.2 (1.3–7.5) 0.007
Acute gain 0.5 (0.2–1.0) 0.06
*Ambrose et al. classification (30). †Modified scheme from American College of Cardiology/American Heart Association Task Force classification (9).
‡Presence of .75% diameter stenosis in two or three major epicardial vessels.
CRP 5 C-reactive protein; PTCA 5 percutaneous transluminal coronary angioplasty; SAA 5 serum amyloid A protein.
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residual stenosis were the most powerful independent pre-
dictors of restenosis and major cardiac adverse events at
follow-up (Fig. 4).
DISCUSSION
To our knowledge, this prospective study is the first to
provide evidence that, in a consecutive group of patients
undergoing single vessel PTCA, early complications and
late restenosis can be predicted with a reasonable accuracy
by measurements easily obtained before the procedure.
Early adverse events. Normal CRP levels had a 100%
negative predictive value for early adverse events and iden-
tified a subset of patients (43% of the whole population)
who did not require additional treatments until hospital
discharge. Inconsistent and weak correlations with early
complications following PTCA were reported for female
gender (8), extreme age (7), diabetes (8), multivessel disease
(6,8), lesion characteristics (8–10) and hemostatic variables
(11,12). Evidence of intracoronary thrombus was found to
be a more consistent predictor of early adverse events
(6,8,10), but its practical value is limited by its low preva-
lence in the baseline angiogram (10). In clinical practice,
unstable angina is the most important predictor of acute
complications following PTCA (2,3,6); however, our obser-
vation that serum CRP levels are even stronger predictors of
early adverse events suggests that the degree of activation of
inflammatory cells is a more important determinant of early
outcome after PTCA than clinical instability. Elevated SAA
levels had a similar prognostic value to CRP levels. Con-
versely, fibrinogen failed to show a prognostic value in
unstable angina patients and for early adverse events. This
may be due to a smaller dynamic range of fibrinogen (lower
increase and longer half-life than CRP and SAA) and to the
fact that fibrinogen levels depend not only on the produc-
tion rate but also on its consumption rate, influenced by
anticoagulant drugs.
Restenosis. Normal CRP levels had a negative predictive
value of 73% and identified a subset of patients (47% of our
population) showing, in the presence of #30% residual
stenosis, a restenosis rate as low as 18%. Conversely, high
CRP levels had a positive predictive value of 63% and
identified a subset of patients (53% of our population) with
an unacceptable restenosis rate, regardless of the intrapro-
cedural angiographic result (restenosis ranging from 44% to
77% according to residual stenosis).
Unstable angina (5,13), diabetes (13), serum levels of
fibrinogen (17), lipoprotein (a) (18), indexes of fibrinolysis
(15) and of platelet function (15) and a number of lesion-
Figure 3. Observed incidence of clinical restenosis according to
CRP levels and residual diameter stenosis. Elevated levels of CRP
(.0.3 mg/dl) (solid bars) compared with low levels (open bars)
were associated with higher restenosis rate in patients with #30%
residual stenosis (18% vs. 44%) and in patients with .30% residual
stenosis (37% vs. 77%). CRP 5 C-reactive protein.
Figure 4. Event-free survival from clinical restenosis (panel A) and from major adverse cardiac events (e.g., death, myocardial infarction
or need for coronary revascularization) (panel B) at one year by preprocedural levels of CRP (multivariate Cox regression analysis). Among
all clinical, angiographic and procedural variables considered, elevated CRP levels were the most powerful independent predictor of clinical
restenosis (RR 5 2.7, CI 5 1.4–5.0, p 5 0.002) and of major adverse cardiac events at follow-up (RR 5 2.8, CI 5 1.4–5.8, p 5 0.005).
Dotted line 5 I tertile of CRP levels; dashed line 5 II tertile of CRP levels; solid line 5 III tertile of CRP levels. CRP 5 C-reactive
protein.
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and procedural-related variables (13,14) were reported to
predict restenosis, but with a low predictive value. Our
results confirm the prognostic value of residual stenosis, but
they also show that CRP levels before the procedure are the
most powerful predictor of restenosis, even in patients with
a good angiographic result.
Pathophysiologic implications. Acute complications fol-
lowing PTCA are commonly due to thrombus formation or
vessel dissection (2). Activation of inflammatory cells may
promote acute complications by increasing procoagulant
activity (19) and by increasing the risk of dissection and of
plaque hemorrhage, through an enhanced synthesis of
matrix metalloproteinases (20). Accordingly, enhanced in-
traprocedural thrombin generation (11) and preprocedural
platelet activation (12) have been reported in patients
undergoing acute occlusion and acute ischemic events after
PTCA.
Restenosis has often been regarded as an inevitable local
healing process following PTCA. However, the bimodal
distribution of late lumen loss, demonstrated following
balloon PTCA (32) and stenting (33), as well as the
clustering of restenosis in patients with multivessel PTCA
(34), suggests that restenosis is not necessarily a uniform
vessel wall response to balloon injury but may occur in some
lesions and in some patients but not in others. The
independent predictive value of residual stenosis and acute-
phase reactants suggests the presence of at least two different
components operating in the restenotic process: a mechan-
ical component mainly operating in patients with a subop-
timal dilation of the lesion at the end of PTCA and an
inflammatory component, mainly operating in patients with
preprocedural elevated levels of acute phase reactants and
probably causing an enhanced vessel response to balloon
injury.
Our results are consistent with the recent observation that
enhanced cytokine synthesis by peripheral blood monocytes
evaluated in vitro before PTCA predicts late lumen loss (16)
and suggest that preprocedural activation of inflammatory
cells may influence intimal hyperplasia and vascular remod-
eling.
Study limitations. The excellent negative predictive value
of preprocedural levels of CRP or SAA found in this study
needs to be considered cautiously due to the relatively small
number of patients (and events). However, the prognostic
value of these markers, if confirmed in larger clinical studies,
could contribute to optimizing therapeutic resources in the
complex scenario of interventional cardiology (4,5).
Another limitation of our study is the lack of repeat
angiography in asymptomatic patients. However, an in-
creasing number of studies are focusing on clinical more
than on angiographic restenosis. Accordingly, we were more
interested in risk stratification of patients undergoing bal-
loon PTCA rather than the pathophysiologic mechanisms
of restenosis. Finally, the role of inflammation in restenosis
might be assessed more easily after stenting, which is not
affected by the mechanical component of restenosis (e.g.,
suboptimal dilation and vessel recoil). In a recent study,
CRP levels were found to predict restenosis following stent
implantation (35).
Conclusions. Our study shows that serum levels of CRP
before PTCA provide a more powerful predictor of both
acute complications and clinical restenosis than clinical
presentation and other risk factors considered thus far. Low
CRP levels before the procedure may help identify patients
with a good outcome when treated by conventional balloon
PTCA. Therefore, for a better resource administration in
interventional cardiology and until specific causes of acute
complications and restenosis are identified, complex and
expensive therapeutic tools, such as anti-glycoprotein IIb/
IIIa agents (4) and stenting (5), may be reserved for patients
with high levels of CRP who are at the highest risk of
in-hospital adverse events and late restenosis.
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